Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$31.51 USD
-1.13 (-3.46%)
Updated Jun 13, 2024 04:00 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Corcept Therapeutics Incorporated [CORT]
Reports for Purchase
Showing records 1 - 20 ( 224 total )
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Catalyst-Rich 2024; New $40 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Positive Clinical Data Underscores Relacorilant Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Promising Data Indicate an Expanding Market; PT Up to $38; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Remain Bullish on Cushing Syndrome Franchise; Lowering PT to $28; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department